ArticleJournal of nanobiotechnology2026
Nanobody-based bioPROTAC for viral protein degradation provides an antiviral strategy for porcine arterivirus.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundProteolysis-targeting chimeras (PROTACs) are powerful tools for targeted protein degradation and are expected to contribute to a promising strategy for next-generation precision therapeutic antiviral drug development. Nanobody-based bioPROTACs can directly bind to protein and mediate target protein degradation, providing a potential antiviral strategy for RNA viruses featuring error-prone replication. Here, we aimed to establish a modular speckle-type POZ protein (SPOP)-derived bioPROTAC platform that enabled rapid antiviral drug construction through the substitution of a target protein-specific nanobody.
resultsUsing porcine reproductive and respiratory syndrome virus (PRRSV) as a model pathogen, bioPROTACs molecules were successfully constructed by flexibly fusing nanobodies against PRRSV nonstructural protein 9 (Nsp9, viral RdRp) to the BTB domain of SPOP. BioPROTACs demonstrated specific degradation of target proteins in a dose-dependent manner, and a bivalent nanobody configuration enhanced the degradation efficiency to greater than 60%. BioPROTACs exhibited antiviral activity against multi-lineages of PRRSV and significantly potentiated the antiviral efficacy of non-neutralizing nanobodies in vitro. Furthermore, intravenous delivery of bioPROTAC-encoding constructs in mice achieved significant reduction of target protein levels within 24 h, demonstrating efficient in vivo degradation capability. Moreover, the combined administration of bioPROTACs via the mRNA-LNP system suppressed PRRSV proliferation and transmission in piglets, which was characterized by reduced viremia, alleviated lung damage, and a decrease in the piglet mortality rate to 25%. Importantly, we revealed that the subcellular localization of both the target protein and bioPROTACs determined the degradation pathway, confirming that cytoplasmic 9nb-SPOP
conclusionThe aim of the current study was to develop and validate modular bioPROTACs targeting essential viral proteins. We constructed the degraders by fusing target-specific nanobodies to the BTB domain of SPOP. More importantly, a combination of bioPROTACs targeting different stages of viral replication, delivered via mRNA-LNPs, suppressed viral replication in a pig model. These findings offer valuable insights into the target degradation mechanisms of SPOP-derived bioPROTACs and provide a foundation for the design of antivirals that have activity against multi-lineages of porcine arterivirus and overcome drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.